Continuous Glucose Monitoring Market Report by Component, End User, Country and Company Analysis 2026-2034

Continuous Glucose Monitoring (CGM) Market Size and Forecast 2026-2034

Watch Market is expected to reach US$ 19.2 billion by 2034 from US$ 8.43 billion in 2025, with a CAGR of 9.58% from 2026 to 2034. Rising diabetes prevalence, strong adoption of connected insulin-delivery systems, FDA-cleared next-generation sensors, increasing availability of OTC devices, and growing demand for real-time glucose insights collectively accelerate global CGM market expansion across clinical, wellness, and home-monitoring environments.

Continuous Glucose Monitoring (CGM) Industry Overview

Continuous Glucose Monitoring (CGM) systems track glucose levels in real time by measuring interstitial fluid through a small sensor placed under the skin. These systems transmit readings to smartphones, receivers, or insulin pumps, providing continuous trends rather than isolated finger-stick snapshots. CGM devices alert users to rising or falling glucose levels, helping prevent dangerous highs and lows while improving long-term glycemic control. They benefit people with Type 1 and Type 2 diabetes and increasingly support wellness users seeking metabolic insights. By enabling data-driven decision-making, CGM technology enhances treatment outcomes, reduces complications, and improves overall diabetes management.

Global CGM demand is expanding due to the rising burden of diabetes, growing acceptance of connected care, and continuous improvements in sensor longevity and accuracy. FDA approvals for advanced devices accelerate adoption by simplifying access and supporting integrated diabetes-management ecosystems. The shift toward automated insulin-delivery systems further strengthens CGM use, while OTC availability broadens the market beyond insulin users. Increasing consumer interest in metabolic health, paired with expanding reimbursement support, drives uptake across clinical and home settings. As technology evolves toward smaller, more affordable, and more interoperable systems, CGM adoption continues to grow worldwide.

Growth Drivers for the Continuous Glucose Monitoring (CGM) Market

Integration of CGM With Smart Insulin Delivery Systems

Interoperability between CGM devices and connected insulin-delivery solutions is one of the strongest market accelerators. In July 2024, Medtronic plc received FDA approval for its Simplera CGM, engineered to link seamlessly with the company's Smart Multiple Daily Injection System and InPen. This integration strengthens the development of closed-loop and semi-automated insulin systems, reducing manual dosing burdens for users. As more patients and clinicians adopt comprehensive digital-diabetes ecosystems, demand for interoperable CGMs increases. Simplera's streamlined design, improved wearability, and connectivity highlight the industry's shift toward user-friendly, minimally invasive, and data-driven solutions. Such ecosystem-based innovation expands CGM adoption among both new and experienced users while reinforcing the long-term trend toward automated insulin delivery.

Expansion of OTC and Wellness-Focused CGM Devices

Broader accessibility is transforming the CGM landscape, especially among people with Type 2 diabetes who do not use insulin. In March 2024, DexCom, Inc. secured FDA approval for Stelo, an over-the-counter CGM with a 15-day sensor life that can be purchased without a prescription. This milestone opens the market to millions of individuals seeking glucose insights for metabolic health, weight management, or preventative care. By eliminating prescription barriers, OTC CGMs encourage earlier monitoring, increase user autonomy, and expand the addressable population far beyond traditional insulin-dependent users. The wellness segment's rapid growth, combined with rising interest in personalized health data, positions OTC CGMs as a major long-term growth driver.

Advancements in Hybrid Closed-Loop Ecosystems

Greater connectivity across diabetes-management platforms is accelerating CGM adoption by offering more automated and reliable glycemic control. In January 2024, Abbott Laboratories announced that its FreeStyle Libre 2 Plus sensor is now compatible with Tandem Diabetes Care's Tandem t:slim X2 insulin pump through the Control-IQ hybrid closed-loop algorithm. This integration allows users to benefit from automated insulin adjustments based on continuous glucose readings. Hybrid closed-loop systems reduce the frequency of hypoglycemia and improve time-in-range, driving stronger clinical recommendations. As more CGMs adopt multi-platform compatibility, patient choice improves and ecosystem adoption accelerates. These innovations push CGM systems toward becoming central components of advanced digital-diabetes management.

Challenges in the Continuous Glucose Monitoring (CGM) Market

High Costs and Uneven Reimbursement

Despite rapid technological improvement, the cost of CGM devices remains a major barrier to widespread adoption. Many users-especially in low-income populations-struggle with recurring expenses for sensors, transmitters, and accessories. Insurance coverage varies significantly by region, disease severity, and insurer policies, creating inconsistent affordability. For non-insulin-using Type 2 diabetics and wellness users, reimbursement is often limited or nonexistent. These financial barriers delay adoption, reduce adherence, and widen disparities between patient groups. Manufacturers face the challenge of reducing prices while maintaining high product accuracy, reliability, and regulatory compliance. Without improved reimbursement frameworks, CGM growth may remain concentrated in higher-income markets.

Data Overload and Integration Barriers

CGM devices generate large volumes of glucose data, which can overwhelm new users and complicate clinical interpretation. Not all healthcare providers are equipped with the time, training, or digital infrastructure required to analyze continuous glucose trends effectively. Integrating CGM data into electronic health systems can also be inconsistent, slowing adoption in traditional healthcare settings. Some users struggle with alarm fatigue, connectivity issues, or sensor-calibration concerns, which may reduce long-term adherence. Ensuring interoperability among pumps, apps, and healthcare platforms adds further complexity. Addressing usability, training, and data-management challenges is essential to optimizing clinical outcomes and supporting sustainable CGM market growth.

United States Continuous Glucose Monitoring (CGM) Market

The U.S. is the largest CGM market, driven by high diabetes prevalence, strong reimbursement coverage, and rapid adoption of automated insulin-delivery systems. OTC CGM availability and continuous FDA approvals accelerate consumer access. Major players like Dexcom, Abbott, and Medtronic dominate the landscape with interoperable, digital-health-focused solutions. Increasing demand for remote monitoring, telehealth integration, and employer-sponsored wellness programs further strengthens market expansion. Strong clinical guidelines and physician familiarity also support CGM use across both Type 1 and Type 2 diabetes populations. The combination of innovation, favorable regulation, and rising health-data awareness ensures continued CGM growth in the U.S.

Germany Continuous Glucose Monitoring (CGM) Market

Germany's CGM market benefits from strong healthcare infrastructure, widespread insurance reimbursement, and early adoption of advanced diabetes-management technologies. Patients with Type 1 diabetes often receive comprehensive coverage for CGM devices, and recent policy shifts are expanding access for Type 2 diabetics. German physicians emphasize data-driven care, increasing reliance on CGM trend analysis. The country also has a growing interest in digital health platforms that integrate CGM data for remote consultations. While regulatory standards are stringent, they enhance device quality and patient safety. Rising diabetes prevalence, particularly among older adults, combined with a highly educated patient population, supports steady CGM growth.

China Continuous Glucose Monitoring (CGM) Market

China's CGM market is expanding rapidly due to rising Type 2 diabetes rates, growing public health awareness, and greater interest in smart-health technologies. Increasing urbanization and lifestyle changes have elevated metabolic-disorder prevalence, encouraging earlier adoption of glucose-monitoring tools. While affordability challenges persist, investments from domestic manufacturers are reducing costs and increasing accessibility. Government healthcare initiatives are improving diabetes screening and management nationwide, supporting CGM integration in hospitals and specialty clinics. Digital health platforms and mobile-health ecosystems further accelerate adoption among tech-savvy consumers. As distribution channels expand and sensor literacy improves, China remains a high-growth region for CGM technologies.

Saudi Arabia Continuous Glucose Monitoring (CGM) Market

Saudi Arabia's CGM market is growing due to high diabetes prevalence, especially among adults with Type 2 diabetes. Strong government investment in healthcare modernization under Vision 2030 supports expanded access to advanced monitoring technologies. Physicians increasingly recommend CGM for improved glycemic control and patient self-management. Rising income levels, coupled with growing awareness of diabetes complications, encourage adoption of premium CGM devices. Pharmacies and private clinics continue to expand their offerings, and digital-health integration is improving patient follow-up. While reimbursement gaps remain a barrier, increasing insurance coverage and strong demand for preventative care drive continuing market growth.

Recent Developments in Continuous Glucose Monitoring (CGM) Market

• June 2025: Tandem Diabetes and Abbott initiated joint development of an integrated glucose-ketone sensor designed to help reduce the risk of diabetic ketoacidosis by enabling earlier detection and intervention.
• May 2025: Glucotrack secured approval from Australia's HREC to begin clinical trials for its implantable continuous glucose monitoring system, marking a significant step toward expanding next-generation CGM solutions in the region.
• April 2025: DexCom received FDA clearance for its Dexcom G7 15-Day CGM system for U.S. adults aged 18 and older, extending sensor wear time and improving convenience for diabetes self-management.
• June 2025: U.S. Health Secretary Robert F. Kennedy Jr. announced a nationwide HHS initiative-"Making America Healthy Again"-to encourage widespread adoption of wearable health-monitoring technologies, including CGMs. The program aims to lower national diabetes-related expenses by promoting proactive, real-time monitoring.
• September 2024: Senseonics obtained FDA approval for the Eversense 365, the first implantable CGM with up to one year of wear. As an iCGM-qualified device, it supports seamless integration with compatible insulin pumps, offering users longer-term, low-maintenance glucose tracking.

Continuous Glucose Monitoring Market Segments

Component

• Sensors
• Transmitters
• Receivers

End User

• Hospitals
• Homecare Settings
• Others

Countries

North America

• United States
• Canada

Europe

• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• Netherlands
• Turkey

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Thailand
• Malaysia
• Indonesia
• New Zealand

Latin America

• Brazil
• Mexico
• Argentina

Middle East & Africa

• South Africa
• Saudi Arabia
• UAE

All the Key players have been covered from 5 Viewpoints:

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Key Players Analysis

• Abbott Laboratories
• Roche
• Tandem Diabetes Care
• DexCom Inc.
• Senseonics Holdings Inc.
• Ypsomed Holding AG
• Medtronic Plc.
• i-Sens Inc.